464 related articles for article (PubMed ID: 14960258)
21. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.
McCloskey EV; Guest JF; Kanis JA
Drugs; 2001; 61(9):1253-74. PubMed ID: 11511021
[TBL] [Abstract][Full Text] [Related]
22. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates in multiple myeloma.
Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
Cochrane Database Syst Rev; 2002; (3):CD003188. PubMed ID: 12137679
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
25. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates: biological response modifiers in breast cancer.
Paterson AH
Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates for advanced prostate cancer.
Macherey S; Monsef I; Jahn F; Jordan K; Yuen KK; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006250. PubMed ID: 29278410
[TBL] [Abstract][Full Text] [Related]
28. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
[TBL] [Abstract][Full Text] [Related]
29. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
Body JJ
Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
[TBL] [Abstract][Full Text] [Related]
33. "The use of bisphosphonates to treat skeletal complications in solid tumours".
D'Oronzo S; Wood S; Brown JE
Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
[TBL] [Abstract][Full Text] [Related]
34. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates in the treatment of metastatic breast cancer.
Body JJ
J Mammary Gland Biol Neoplasia; 2001 Oct; 6(4):477-85. PubMed ID: 12013536
[TBL] [Abstract][Full Text] [Related]
36. [Bisphosphonates and bone metastases].
Lortholary A; Jadaud E; Berthaud P
Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
[TBL] [Abstract][Full Text] [Related]
37. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
40. Should bisphosphonates be standard therapy for bone pain?
Paterson AH
Support Care Cancer; 1997 May; 5(3):200-4. PubMed ID: 9176965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]